Reliability and validity of the visual analogue scale for disability in patients with chronic musculoskeletal pain.
Anne M Boonstra, Henrica R Schiphorst Preuper, Michiel F Reneman...
https://pubmed.ncbi.nlm.nih.gov/18467932/Actively Recruiting
Led by Maxx Orthopedics Inc · Updated on 2026-06-26
200
Participants Needed
2
Research Sites
8 weeks
Total Duration
Researchers are evaluating the performance and safety of the Maxx Orthopedics Freedom Total Knee System with a new femoral component made from polyether-ether-ketone PEEK in patients with knee osteoarthritis. This investigational device exemption IDE study focuses on comparing this PEEK femoral component to a similar design made from cobalt-chromium CoCr alloy. The study aims to monitor how well the device works and its safety over time in adults with moderate knee impairment. Participants will undergo primary total knee arthroplasty using the Freedom Total Knee System with the PEEK femoral component. This is a single-arm, multi-center trial where 200 patients will receive the PEEK device. Their results will be compared to matched historic controls from a product registry. The study uses FDA-approved instrumentation to assist the knee surgery and includes follow-up to assess post-operative care, complications, and device performance. During the study, participants will be evaluated through clinical visits and assessments at multiple time points up to 24 months after surgery. Researchers will use measures such as the Knee Society Score, Knee Injury and Osteoarthritis Outcome Score, PROMIS Global-10, Visual-Analog Scale, and Forgotten Joint Score to monitor outcomes. Patient records will be reviewed for any complications or re-operations. The total study duration extends from surgery through 24 months of follow-up to assess long-term device safety and function.
CONDITIONS
MultiCenter IDE Study of the PEEK-OPTIMA™ Femoral Component vs a CoCr Alloy TKA Femoral Component of Similar Design
N
Nach Dave, M.S., R.Ph.
C
Corey Perine, BS, MBA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Maxx Orthopedics Inc
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | PEEK-OPTIMA™ femoral component TKA (Investigational device as used in trial) | CoCr alloy femoral component TKA (current standard device) |
|---|---|---|
| What is it? | Investigational device: total knee arthroplasty performed with a PEEK-OPTIMA™ femoral component, designed to replace the femur's articulating surface in patients with end-stage knee osteoarthritis. | Established device: primary total knee arthroplasty using a cobalt-chromium alloy femoral component, the widely used standard for implant replacement in advanced knee osteoarthritis. |
| Role in the study | The cohort receives primary TKA surgery using the PEEK-OPTIMA™ femoral device. Outcomes are prospectively measured for up to 24 months to assess function and device safety. | External comparator for clinical context; not assigned within this trial. Represents current standard care for the same population and indication. |
| Primary use | Used in surgical replacement of the knee joint femoral surface for adults with advanced knee osteoarthritis. | Implant for knee joint femoral surface replacement, routinely used in TKA procedures for end-stage osteoarthritis. |
| How is it given or performed? | Participants undergo surgical implantation of the PEEK-OPTIMA™ femoral component as part of primary TKA. Standard peri-operative care protocols are followed. | Surgical implantation of cobalt-chromium alloy femoral component performed using established TKA methods, with peri-operative protocols ensuring recovery and outcome assessment. |
| Evidence status | Investigational device; no published patient outcome evidence for clinical effectiveness or safety. Trial is ongoing, with outcome measures including Knee Society Score, KOOS-JR, PROMIS, VAS, and FJS-12 to be collected up to 24 months. | Extensively published evidence supports effectiveness, functional improvement, and peri-operative safety for primary TKA with CoCr alloy femoral components in knee osteoarthritis. Validated outcomes include PROMIS-10, KOOS-JR, Knee Society Score, and Forgotten Joint Score. |
| Important limitations | Clinical safety and long-term device performance remain unestablished; device is investigational and no published durability, adverse event, or revision rates are available for PEEK femoral components in TKA. | CoCr alloy devices may be associated with known limitations including metal hypersensitivity, wear-related issues, and eventual implant revision. Long-term follow-up is necessary due to risk of failure or complications, though implant durability is well established. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 24 months
Participants receive primary total knee arthroplasty with the investigational PEEK femoral component.
Multiple follow-up visits at 3-6 weeks, and 3, 6, 12, and 24 months post-surgery
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Anne M Boonstra, Henrica R Schiphorst Preuper, Michiel F Reneman...
https://pubmed.ncbi.nlm.nih.gov/18467932/J Shim, D F Hamilton
https://pubmed.ncbi.nlm.nih.gov/31256677/Esa Jämsen, Timo Puolakka, Antti Eskelinen...
https://pubmed.ncbi.nlm.nih.gov/23244785/Morten G Thomsen, Roshan Latifi, Thomas Kallemose...
https://pubmed.ncbi.nlm.nih.gov/26937689/Stephen Lyman, Yuo-Yu Lee, Patricia D Franklin...
https://pubmed.ncbi.nlm.nih.gov/26926773/J N Insall, L D Dorr, R D Scott...
https://pubmed.ncbi.nlm.nih.gov/2805470/Keith R Berend, Adolph V Lombardi, Thomas H Mallory
https://pubmed.ncbi.nlm.nih.gov/15744696/Maxx Orthopedics Inc
Lead Sponsor